SIX •
Healthcare •
Biotechnology •
Quote as of 09/08/2026 17:31
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeSIX
Market Capitalization5.32 mln
Float97.06 mln
Earnings Date10/01/2026
Piotroski F-Score
1
/ 9
Very weak
Beneish M-Score
-0.35
Highly suspicious
Relative Strength
18
/ 100
Significantly lagging
Debt / Equity
0.03
Debt-free
ROE
-118
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Addex Therapeutics is a Swiss drug discovery company founded in 2002 and headquartered in Geneva, focused on developing treatments for neurological conditions. Its most advanced drug candidate, Dipraglurant, is being studied for recovery after stroke or brain injury and for managing involuntary movements caused by Parkinson's disease medication. The company also has additional programs targeting pain, anxiety, addiction, chronic cough, and bladder problems. Addex works alongside major partners including Janssen Pharmaceuticals and Indivior to advance several of these treatments toward patients.
